Illumina Stock Forecast, Price & News

Illumina (NASDAQ:ILMN) Frequently Asked Questions

Is Illumina a buy right now?

10 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Illumina in the last year. There are currently 2 sell ratings, 3 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" Illumina stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ILMN, but not buy additional shares or sell existing shares.
View analyst ratings for Illumina or view top-rated stocks.

How has Illumina's stock price been impacted by COVID-19?

Illumina's stock was trading at $246.01 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, ILMN stock has increased by 50.3% and is now trading at $369.79.
View which stocks have been most impacted by COVID-19.

When is Illumina's next earnings date?

Illumina is scheduled to release its next quarterly earnings announcement on Thursday, February 10th 2022.
View our earnings forecast for Illumina.

How were Illumina's earnings last quarter?

Illumina, Inc. (NASDAQ:ILMN) released its earnings results on Thursday, November, 4th. The life sciences company reported $1.45 EPS for the quarter, topping the Zacks' consensus estimate of $1.24 by $0.21. The life sciences company had revenue of $1.11 billion for the quarter, compared to analysts' expectations of $1.04 billion. Illumina had a trailing twelve-month return on equity of 15.03% and a net margin of 21.17%. The company's revenue was up 39.3% compared to the same quarter last year. During the same period in the prior year, the company earned $1.02 EPS.
View Illumina's earnings history.

What guidance has Illumina issued on next quarter's earnings?

Illumina issued an update on its FY 2021 earnings guidance on Thursday, November, 25th. The company provided EPS guidance of $5.500-$5.600 for the period, compared to the Thomson Reuters consensus EPS estimate of $5.730. The company issued revenue guidance of $4.41 billion-$4.41 billion, compared to the consensus revenue estimate of $4.35 billion.

What price target have analysts set for ILMN?

10 brokerages have issued 1 year price objectives for Illumina's stock. Their forecasts range from $335.00 to $570.00. On average, they anticipate Illumina's share price to reach $435.18 in the next twelve months. This suggests a possible upside of 17.7% from the stock's current price.
View analysts' price targets for Illumina or view top-rated stocks among Wall Street analysts.

Who are Illumina's key executives?

Illumina's management team includes the following people:

• Francis A. deSouza, President, Chief Executive Officer & Director
• Robert P. Ragusa, Chief Operations Officer
• Sam A. Samad, Chief Financial Officer & Senior Vice President
• Phillip G. Febbo, Chief Medical Officer (LinkedIn Profile)
• Alex Aravanis, CTO, Head-Research & Product Development

What is Francis deSouza's approval rating as Illumina's CEO?

496 employees have rated Illumina CEO Francis deSouza on Glassdoor.com. Francis deSouza has an approval rating of 92% among Illumina's employees. This puts Francis deSouza in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Illumina's key competitors?

Some companies that are related to Illumina include Thermo Fisher Scientific (TMO), Agilent Technologies (A), Mettler-Toledo International (MTD), PerkinElmer (PKI), Bio-Rad Laboratories (BIO), Waters (WAT), Charles River Laboratories International (CRL), Bio-Techne (TECH), Bruker (BRKR), Pacific Biosciences of California (PACB), Fluidigm (FLDM), Harvard Bioscience (HBIO), aTyr Pharma (LIFE) and BG Medicine (BGMD).
View all of ILMN's competitors.

What other stocks do shareholders of Illumina own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Illumina investors own include NVIDIA (NVDA), Alibaba Group (BABA), Tesla (TSLA), Netflix (NFLX), Walt Disney (DIS), PayPal (PYPL), salesforce.com (CRM), Adobe (ADBE), Visa (V) and Micron Technology (MU).

What is Illumina's stock symbol?

Illumina trades on the NASDAQ under the ticker symbol "ILMN."

Who are Illumina's major shareholders?

Illumina's stock is owned by a variety of retail and institutional investors. Top institutional investors include Baillie Gifford & Co. (14.06%), Edgewood Management LLC (4.42%), Wellington Management Group LLP (2.09%), Geode Capital Management LLC (1.68%), Polen Capital Management LLC (1.73%) and Janus Henderson Group PLC (1.00%). Company insiders that own Illumina stock include Aimee L Hoyt, Alexander Aravanis, Charles Dadswell, Frances Arnold, Francis A Desouza, Jay T Flatley, Karen K Mcginnis, Mostafa Ronaghi, Oene Mark Van, Omead Ostadan, Phillip G Febbo, Robert P Ragusa, Sam Samad, Susan H Tousi and Susan H Tousi.
View institutional ownership trends for Illumina.

Which institutional investors are selling Illumina stock?

ILMN stock was sold by a variety of institutional investors in the last quarter, including New York State Common Retirement Fund, Sands Capital Management LLC, First Hawaiian Bank, Morgan Stanley, Baillie Gifford & Co., Wellington Management Group LLP, Capital World Investors, and Janus Henderson Group PLC. Company insiders that have sold Illumina company stock in the last year include Aimee L Hoyt, Alexander Aravanis, Charles Dadswell, Francis A Desouza, Jay T Flatley, Mostafa Ronaghi, Phillip G Febbo, and Susan H Tousi.
View insider buying and selling activity for Illumina or view top insider-selling stocks.

Which institutional investors are buying Illumina stock?

ILMN stock was acquired by a variety of institutional investors in the last quarter, including Johnson & Johnson, Edgewood Management LLC, Two Sigma Advisers LP, Liontrust Investment Partners LLP, Renaissance Technologies LLC, MWG Management Ltd., Arrowstreet Capital Limited Partnership, and Alliancebernstein L.P..
View insider buying and selling activity for Illumina or or view top insider-buying stocks.

How do I buy shares of Illumina?

Shares of ILMN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Illumina's stock price today?

One share of ILMN stock can currently be purchased for approximately $369.79.

How much money does Illumina make?

Illumina has a market capitalization of $57.80 billion and generates $3.24 billion in revenue each year. The life sciences company earns $656 million in net income (profit) each year or $6.09 on an earnings per share basis.

How many employees does Illumina have?

Illumina employs 7,850 workers across the globe.

Does Illumina have any subsidiaries?

The following companies are subsidiares of Illumina: Advanced Liquid Logic Inc., Affomix Corporation, BlueBee, BlueBee Belgium BVBA, BlueBee Holding BV, BlueGnome Ltd, BlueGnome Ltd., Conexio Genomics, Conexio Genomics Pty Ltd., Edico Genome, Edico Genome Corp., Enancio, Enancio SAS, Epicentre Biotechnologies, Epicentre Technologies Corporation, FC Ops Corp., GenoLogics, Grail, Helixis, Illumina (China) Scientific Co Ltd, Illumina AB, Illumina Australia Pty. Ltd., Illumina Belgium BVBA, Illumina Brasil Produtos de Biotecnologia Ltda., Illumina Cambridge Ltd., Illumina Canada Inc., Illumina Canada ULC, Illumina Denmark ApS, Illumina Finland Oy, Illumina France Holding Sarl, Illumina France Sarl, Illumina GmbH, Illumina Hong Kong Limited, Illumina Iceland ehf, Illumina India Biotechnology Private Limited, Illumina Ireland Commercial Limited, Illumina Italy S.r.l., Illumina K.K. Japan, Illumina Korea Ltd., Illumina Netherlands B.V., Illumina New Zealand Limited, Illumina Norway AS, Illumina Productos de Espana S.L.U., Illumina Rus, Illumina Rus LLC, Illumina Shanghai (Trading) Co Ltd, Illumina Shanghai (Trading) Co Ltd Beijing Branch, Illumina Shanghai (Trading) Co. Ltd., Illumina Singapore Pte. Ltd., Illumina Software Inc., Illumina Switzerland GmbH, Illumina US Manufacturing Operations Inc., Liquid Logic, Moleculo, NextBio, Solexa, Verinata Health, Verinata Health Inc., and thromboDx BV.

When was Illumina founded?

Illumina was founded in 1998.

What is Illumina's official website?

The official website for Illumina is www.illumina.com.

Where are Illumina's headquarters?

Illumina is headquartered at 200 ILLUMINA WAY, SAN DIEGO CA, 92122.

How can I contact Illumina?

Illumina's mailing address is 200 ILLUMINA WAY, SAN DIEGO CA, 92122. The life sciences company can be reached via phone at (858) 202-4500, via email at [email protected], or via fax at 858-202-4766.